In addition, testing for Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency to safely administer the radical cure for P. vivax cases [30], which have contributed 90% of malaria burden in Cambodia since 2020, provides an opportunity for VMWs to fill in the gap in community case referral. This evidence concerns the gene G6PD and malaria.